GCG and obesity due to melanocortin 4 receptor deficiency: In conclusion, when considering adding a GLP-1 analog to the metabolic treatment of a patient with PCOS, the primary indication and intended use should be to treat obesity (with a BMI > 30), or a BMI > 27, accompanied by concomitant metabolic dysfunctions such as hypertension, dyslipidemia, obstructive sleep apnea, impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes.